{"filing":{"accession_number":"0001104659-26-070173","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"tm2616851d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_8k.htm"},"events":[{"id":7106,"run_id":6234,"accession_number":"0001104659-26-070173","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Liminatus Pharma entered into a warrant exercise inducement agreement resulting in the issuance of 20,688,000 new Inducement Warrants in a private placement under Section 4(a)(2) and Regulation D Rule 506(b), raising approximately $1.86 million in gross proceeds. The unregistered issuance doubles the warrant position of the holder in exchange for exercising existing warrants at a reduced price and requires a resale registration statement.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3898,"accession_number":"0001104659-26-070173","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into a warrant exercise inducement agreement resulting in the issuance of 20,688,000 new warrants (the \"Inducement Warrants\") in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance that doubles the warrant position of the holder in exchange for exercising existing warrants at a reduced price, raising approximately $1.86 million in gross proceeds. The unregistered nature of the new warrants and the requirement for a resale registration statement further confirm this as a material dilutive capital-raising transaction typical of small-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3899,"accession_number":"0001104659-26-070173","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an unregistered issuance of \"Inducement Warrants\" under Section 4(a)(2) and Regulation D Rule 506(b), which are classic private placement exemptions. The warrants (New Black-Scholes Warrant and New Change of Control Warrant) represent dilutive equity securities issued without registration, a material event for investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3901,"accession_number":"0001104659-26-070173","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release announcing \"transactions contemplated by the Inducement Letter Agreement\" under Item 8.01 (Other Events). While the specific nature of these transactions is not detailed in the excerpt provided, an \"Inducement Letter Agreement\" typically relates to equity issuances or compensatory arrangements designed to induce employee participation or financing. Without clearer language indicating whether this is a dilutive equity issuance, executive compensation arrangement, or M\u0026A activity, the most appropriate classification is other_material, as it represents a material transaction announcement that does not fit neatly into more specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":7107,"run_id":6234,"accession_number":"0001104659-26-070173","anchor_item_number":"3.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"Item 3.03 discloses a material modification to the rights of security holders, incorporating Item 1.01 by reference. The specific nature of the modification cannot be fully determined from the available information.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3900,"accession_number":"0001104659-26-070173","item_number":"3.03","item_title":"Material Modification to Rights","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to rights of security holders and incorporates Item 1.01 by reference. Without the full text of Item 1.01, the specific nature of the modification cannot be determined. Item 1.01 typically covers business combinations or material agreements, but the modification itself could relate to M\u0026A activity, dilutive issuance, or another material event. Given the ambiguity and the cross-reference structure, this is classified as other_material pending visibility into the incorporated Item 1.01 content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3898,"accession_number":"0001104659-26-070173","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into a warrant exercise inducement agreement resulting in the issuance of 20,688,000 new warrants (the \"Inducement Warrants\") in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance that doubles the warrant position of the holder in exchange for exercising existing warrants at a reduced price, raising approximately $1.86 million in gross proceeds. The unregistered nature of the new warrants and the requirement for a resale registration statement further confirm this as a material dilutive capital-raising transaction typical of small-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03"},{"id":3899,"accession_number":"0001104659-26-070173","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an unregistered issuance of \"Inducement Warrants\" under Section 4(a)(2) and Regulation D Rule 506(b), which are classic private placement exemptions. The warrants (New Black-Scholes Warrant and New Change of Control Warrant) represent dilutive equity securities issued without registration, a material event for investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03"},{"id":3900,"accession_number":"0001104659-26-070173","item_number":"3.03","item_title":"Material Modification to Rights","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to rights of security holders and incorporates Item 1.01 by reference. Without the full text of Item 1.01, the specific nature of the modification cannot be determined. Item 1.01 typically covers business combinations or material agreements, but the modification itself could relate to M\u0026A activity, dilutive issuance, or another material event. Given the ambiguity and the cross-reference structure, this is classified as other_material pending visibility into the incorporated Item 1.01 content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03"},{"id":3901,"accession_number":"0001104659-26-070173","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release announcing \"transactions contemplated by the Inducement Letter Agreement\" under Item 8.01 (Other Events). While the specific nature of these transactions is not detailed in the excerpt provided, an \"Inducement Letter Agreement\" typically relates to equity issuances or compensatory arrangements designed to induce employee participation or financing. Without clearer language indicating whether this is a dilutive equity issuance, executive compensation arrangement, or M\u0026A activity, the most appropriate classification is other_material, as it represents a material transaction announcement that does not fit neatly into more specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:19:31.536332+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-06-03"}]}